☆Patient Square Capital LP
Quality Q
0.507
AUM ($M)
646
Positions
23
Turnover
0.25
Top-10 wt
80%
Herfindahl
0.213
History (qtrs)
6
Excess Return
—
AI Eval Run AI Eval
Holdings · 35 positions · portfolio value $646M
| Ticker | Name | Activity | Security Type | Weight | Δ Weight | Value ($M) | Shares | Δ Shares | Qtrs Held | Excess Return |
|---|---|---|---|---|---|---|---|---|---|---|
| ☆CUSIP:G76279101 funds › | ROIVANT SCIENCES LTD | TRIM | — | 44.0% | +3.8% | 283.9 | 8,020,928 | -145,119 | 5 | — |
| ☆RVMD funds › | REVOLUTION MEDICINES INC | NEW | — | 8.0% | +8.0% | 51.7 | 276,000 | +276,000 | 1 | — |
| ☆MIRM funds › | MIRUM PHARMACEUTICALS INC | ADD | — | 4.7% | +1.0% | 30.5 | 260,500 | +30,500 | 5 | — |
| ☆ABVX funds › | ABIVAX SA | ADD | — | 4.3% | +1.9% | 27.5 | 206,500 | +85,255 | 4 | — |
| ☆ONC funds › | BEONE MEDICINES LTD | ADD | — | 4.0% | -0.3% | 25.7 | 90,020 | +9,478 | 3 | — |
| ☆PHVS funds › | PHARVARIS N V | ADD | — | 3.6% | +1.1% | 23.2 | 671,209 | +178,209 | 5 | — |
| ☆ARGX funds › | ARGENX SE | TRIM | — | 3.3% | -1.5% | 21.3 | 23,000 | -13,718 | 5 | — |
| ☆UTHR funds › | UNITED THERAPEUTICS CORP DEL | NEW | — | 3.1% | +3.1% | 20.1 | 37,120 | +37,120 | 1 | — |
| ☆BLTE funds › | BELITE BIO INC | TRIM | — | 2.6% | -0.7% | 16.9 | 110,000 | -6,684 | 2 | — |
| ☆COGT funds › | COGENT BIOSCIENCES INC | TRIM | — | 2.5% | -1.5% | 16.4 | 425,000 | -171,000 | 3 | — |
| ☆DBVT funds › | DBV TECHNOLOGIES S A | ADD | — | 2.3% | -0.3% | 14.9 | 909,474 | +215,940 | 3 | — |
| ☆XENE funds › | XENON PHARMACEUTICALS INC | TRIM | — | 2.1% | -0.3% | 13.3 | 220,000 | -7,000 | 3 | — |
| ☆BNTX funds › | BIONTECH SE | NEW | — | 1.9% | +1.9% | 12.5 | 134,429 | +134,429 | 1 | — |
| ☆RCUS funds › | ARCUS BIOSCIENCES INC | ADD | — | 1.7% | +1.0% | 11.0 | 355,800 | +160,800 | 3 | — |
| ☆ELVN funds › | ENLIVEN THERAPEUTICS INC | ADD | — | 1.7% | +0.3% | 10.8 | 212,500 | +12,500 | 5 | — |
| ☆DNTH funds › | DIANTHUS THERAPEUTICS INC | ADD | — | 1.6% | +0.2% | 10.5 | 108,000 | +14,118 | 4 | — |
| ☆ALLO funds › | ALLOGENE THERAPEUTICS INC | ADD | — | 1.6% | +0.1% | 10.5 | 5,050,000 | +1,600,000 | 5 | — |
| ☆EYPT funds › | EYEPOINT INC | TRIM | — | 1.6% | -0.2% | 10.3 | 720,000 | -75,000 | 5 | — |
| ☆ARQT funds › | ARCUTIS BIOTHERAPEUTICS INC | TRIM | — | 1.5% | -0.2% | 9.7 | 370,000 | -30,645 | 3 | — |
| ☆CCCC funds › | C4 THERAPEUTICS INC | NEW | — | 1.2% | +1.2% | 7.5 | 1,608,815 | +1,608,815 | 1 | — |
| ☆IVA funds › | INVENTIVA SA | NEW | — | 1.2% | +1.2% | 7.4 | 1,967,171 | +1,967,171 | 1 | — |
| ☆KYMR funds › | KYMERA THERAPEUTICS INC | TRIM | — | 0.8% | -0.6% | 5.4 | 47,500 | -52,500 | 5 | — |
| ☆FTH funds › | FAETH THERAPEUTICS INC | NEW | — | 0.7% | +0.7% | 4.4 | 175,050 | +175,050 | 1 | — |
| ☆LEGN funds › | LEGEND BIOTECH CORP | EXIT | — | 0.0% | -3.2% | 0.0 | 0 | -990,000 | 0 | — |
| ☆INSM funds › | INSMED INC | EXIT | — | 0.0% | -4.6% | 0.0 | 0 | -157,500 | 0 | — |
| ☆DFTX funds › | DEFINIUM THERAPEUTICS INC | EXIT | — | 0.0% | -1.1% | 0.0 | 0 | -331,000 | 0 | — |
| ☆HROW funds › | HARROW INC | EXIT | — | 0.0% | -1.0% | 0.0 | 0 | -165,209 | 0 | — |
| ☆MRK funds › | MERCK & CO INC | EXIT | — | 0.0% | -1.7% | 0.0 | 0 | -80,000 | 0 | — |
| ☆CELC funds › | CELCUITY INC | EXIT | — | 0.0% | -1.9% | 0.0 | 0 | -95,000 | 0 | — |
| ☆NKTR funds › | NEKTAR THERAPEUTICS | EXIT | — | 0.0% | -2.7% | 0.0 | 0 | -210,000 | 0 | — |
| ☆CTMX funds › | CYTOMX THERAPEUTICS INC. | EXIT | — | 0.0% | -0.9% | 0.0 | 0 | -1,085,790 | 0 | — |
| ☆CATX funds › | PERSPECTIVE THERAPEUTICS INC | EXIT | — | 0.0% | -1.2% | 0.0 | 0 | -1,625,000 | 0 | — |
| ☆ASMB funds › | ASSEMBLY BIOSCIENCES INC | EXIT | — | 0.0% | -0.7% | 0.0 | 0 | -136,315 | 0 | — |
| ☆TARA funds › | PROTARA THERAPEUTICS INC | EXIT | — | 0.0% | -1.0% | 0.0 | 0 | -1,030,846 | 0 | — |
| ☆SYRE funds › | SPYRE THERAPEUTICS INC | EXIT | — | 0.0% | -0.0% | 0.0 | 0 | -1,000 | 0 | — |
Point-in-time history
| Period | AUM ($M) | Positions | Turnover | Top-10 wt | Herfindahl | Quality Q | Skill | Universe |
|---|---|---|---|---|---|---|---|---|
| 2026Q2 | 646 | 23 | 0.25 | 80% | 0.213 | 0.507 | — | in |
| 2026Q1 | 564 | 29 | 0.22 | 73% | 0.178 | 0.501 | — | in |
| 2025Q4 | 467 | 28 | 0.25 | 77% | 0.169 | 0.390 | — | in |
| 2025Q3 | 374 | 24 | 0.14 | 86% | 0.279 | 0.685 | — | in |
| 2025Q2 | 277 | 19 | 0.11 | 90% | 0.286 | 0.762 | — | entered |
| 2025Q1 | 242 | 19 | 0.00 | 89% | 0.297 | 0.000 | — | out |
Long US-equity 13F disclosures only · up to 45-day reporting lag · sells = reduce/avoid, not short.
JSON: /api/signals ·
/api/funds ·
/api/status